Described herein are methods of treating cancer by inducing favorable effects on tumor microenvironment (e.g., including macrophage polarization, cytokine profile, and/or immunophenotype) via administration of nanoparticles (e.g., silica-based ultra-small nanoparticles and nanoparticle conjugates such as nanoparticle drug conjugates). In certain embodiments, the methods may be used in concert with, or as part of, checkpoint inhibition therapy (e.g., anti-PD1) or radiotherapy, or a combination of both radiotherapy and checkpoint inhibitor therapy.

The present disclosure relates to a composition comprising glucoraphanin and its therapeutic use.

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

A reactor for coating particles includes a vacuum chamber configured to hold particles to be coated, a vacuum port to exhaust gas from the vacuum chamber via the outlet of the vacuum chamber, a chemical delivery system configured to flow a process gas into the particles via a gas inlet on the vacuum chamber, one or more vibrational actuators located on a first mounting surface of the vacuum chamber, and a controller configured to cause the one or more vibrational actuators to generate a vibrational motion in the vacuum chamber sufficient to induce a vibrational motion in the particles held within the vacuum chamber.

The solubility and bioavailability properties of meloxicam can be improved by preparing compositions of meloxicam co-crystals and reducing the particle size of (e.g., “nanosizing”) co-crystals. Such compositions with improved dissolution pharmacokinetic properties can be prepared by granulation and blending the co-crystals with extragranular excipients to provide oral solid dosage forms. As a result of the improved properties of the meloxicam oral dosage forms, the compositions may be useful for the treatment of pain, including acute pain.

A method for capturing material extracted from biochar is provided comprising the steps of: (i) providing a biochar; (ii) contacting the biochar with an extraction media, where the extraction media causes the removal of residual compounds from the pores and surface of the biochar, creating a resulting extract comprised of the extraction media and removed compounds; and (iii) collecting the resulting extract. The method also can include other steps of extraction and purification. The method further comprises the step of applying the resulting extract to seeds, plants, soil, other agricultural products, or for use in other applications. A biochar having high levels of soluble signaling compounds is also provided, where the biochar is derived from a biomass source that together with predefined pyrolysis parameters produces resulting biochar having increased levels of soluble signaling compounds that are known to increase seed germination rates and early plant growth. Such soluble signaling compounds can then be collected in a biochar extract by contacting the biochar with an extraction media.

The present disclosure relates to supraparticles loaded with high levels of payload and having controlled payload release profiles. In particular, supraparticles made of mesoporous silica nanoparticles and elecrosprayed with alginic acid which is then coated or formulated with biodegradable materials is disclosed. Such supraparticles may be used in a range of therapeutic applications.

In one aspect, the present disclosure provides knitted component comprising with a first surface and a second surface, the first surface facing opposite the second surface. A pod may have the first surface and the second surface, and an edge region may have the first surface and the second surface, where the edge region at least partially demarcates the pod. A first yarn may substantially form the first surface of the pod, where the first yarn is a fusible yarn. A second yarn may substantially form the second surface of the pod, and the second yarn may substantially form the first surface of the edge region.

Chitosan can be coated, e.g., in 0.06 or 0.6 wt. %, over spherical silica, e.g., HYPS, loaded with spinel ferrites of theoretical formula MFe.sub.2O.sub.4, wherein M is Ni, Cu, Co, and/or Mn, e.g., at 30 wt. %, and cisplatin. Chitosan can be fabricated over Pt or cisplatin) bound CuFe.sub.2O.sub.4-HYPS and CuFe.sub.2O.sub.4-HYPS followed by Pt loading. Cisplatin and Pt-CuFe.sub.2O.sub.4-HYPS-chitosan at 0.025 to 0.5 mg/mL exhibit cytotoxicity against human breast cancer cell line (MCF-7) and human embryonic kidney cells (HEK293), relative to Pt-CuFe.sub.2O.sub.4-HYPS, with Pt-CuFe.sub.2O.sub.4-HYPS-chitosan, showing non-significant anti-cancer effects due to mediated Pt release. Pt-CuFe.sub.2O.sub.4/HYPS and CuFe.sub.2O.sub.4-HYPS-chitosan-Pt reduced cell viability using a different dose effect. Cisplatin in certain composites was less cytotoxic to HEK293 than MCF7, making the a targeted drug delivery system. Inventive composites may improve multifunctional theranostic applications involving pH stimuli, temperature-based drug release, and diagnosis based treatment such as hyperthermia.

Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.